BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

Corporate Breaking News

Home : BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

Aug 21 2019	BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors
LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, today announced that the earlier communicated phase l/lla clinical trial...


Source:https://www.prnewswire.com:443/news-releases/bioinvent-will-conduct-phase-llla-trial-with-bi-1206-in-combination-with-pembrolizumab-keytruda-in-solid-tumors-300904973.html

Related News
» DE-CIX Dallas’ Major Switch Site at DataBank 400 South Akard Now Live » Gatling Drills High-Grade, Near Surface Gold at Cheminis Deposit Including 12.3 g/t Au over 5.0 meters